Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib, Venetoclax, and Obinutuzumab in Mantle Cell Lymphoma
NCT04855695Phase 2Recruiting
- Start
- Jul 2021
- Primary completion
- Jun 2027
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib tablet (Variant 1), venetoclax, obinutuzumab in mantle cell lymphoma (MCL). Started Jul 2021; status: recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)venetoclaxobinutuzumab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT04855695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04855695.